Home Tags Mirvetuximab soravtansine

Tag: Mirvetuximab soravtansine

Clinical Updates Confirming Advances and Meaningful Benefits for Patients

Earlier this year, during the meetings of the American Association for Cancer Research (AACR), held April 16-20 in New Orleans, LA, and the Protein...

ASCO 2016 Emphasizes Collective Wisdom: The Future of Patient-Centered Care and...

Only a few weeks until the start of the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). This year’s ASCO, taking...

ImmunoGen and Merck Evaluate Mirvetuximab Soravtansine in Combination with Pembrolizumab in...

ImmunoGen and Merck, known as MSD outside the United States and Canada, have entered into a clinical research collaboration for the assessment of ImmunoGen's...

Treatment Response to Mirvetuximab Soravtansine Found to be Substantially Greater in...

Findings with mirvetuximab soravtansine (also known as IMGN853 and M9346A-sulfo-SPDB-DM4), a novel folate receptor alpha (FRα)-targeting antibody-drug conjugate being developed by ImmunoGen, a clinical-stage...

ASCO 2015: Advancing Antibody-drug Conjugates in Difficult-to-treat Cancers

With the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO), which was held in Chicago, Illinois, May 29 - June 2,...